Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF

ARCA:THNR Stock Report

Market Cap: US$3.9m

Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Capital Markets Industry Growth10.3%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Earnings Updaten/a

Recent past performance updates

No updates

Recent updates

No updates

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Show section

Revenue & Expenses Breakdown

How Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ARCA:THNR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses

Quality Earnings: Insufficient data to determine if THNR has high quality earnings.

Growing Profit Margin: Insufficient data to determine if THNR's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if THNR's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare THNR's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.

Earnings vs Industry: Insufficient data to determine if THNR's earnings growth over the past year exceeded the Capital Markets industry average.


Return on Equity

High ROE: THNR has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed